Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
Also on December 5, H.C. Wainwright reiterated its Buy rating on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with a price target of $10. This update comes as the company approaches an important data readout for its CX-2051 therapy in colorectal cancer. H.C. Wainwright outlined specific performance benchmarks to measure how successful the upcoming dataset could be. In its most optimistic or “slam dunk” scenario, the firm expects an objective response rate of 25% to 30% or higher, median progression-free survival of at least six months, and Grade 3 diarrhea in less than 5% of patients. H.C. Wainwright also described a “bull case” scenario, which would still be seen as positive. This will include an objective response rate of 15% to 20% or higher, a median progression-free survival of at least five months, and Grade 3 diarrhea in less than 10% of patients. The research firm's analysis included input from Dr. Michael Pishvaian, who was reportedly impressed by the CX-2051's interim data, an
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics Announces Business Update and Company Milestones for 2026GlobeNewswire
- CytomX Therapeutics: EpCAM Is Back, Now Prove It Holds (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress [Yahoo! Finance]Yahoo! Finance
- CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling [Seeking Alpha]Seeking Alpha
- What Analysts Think Is Changing the CytomX Therapeutics Story After Recent Cancer Developments [Yahoo! Finance]Yahoo! Finance
CTMX
Earnings
- 11/6/25 - Miss
CTMX
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CTMX's page on the SEC website